PDX-derived organoids (PDXOs) are three-dimensional, self-organizing in vitro models generated by isolating and culturing cells from established PDX models. Unlike cancer cell line-derived organoids, PDXOs originate from tumors that have been passaged in vivo in immunocompromised mice, a process that enriches for patient-relevant cancer stem cells and maintains the tumor's stromal components and intratumoral heterogeneity more effectively than direct in vitro culture. This model serves as a powerful bridge, capturing the complex biology of the patient's tumor while offering the flexibility and scalability needed for systematic experimental workflows.
PDXOs offer a unique and powerful bridge model for oncology research, enabling rapid, scalable experimentation while maintaining high predictive value.
Preserved Tumor Heterogeneity
Preserve the original tumor's mutational spectrum, gene expression profiles, histological complexity, and intra-tumoral heterogeneity more reliably than long-term 2D cell cultures.
Scalability & High-Throughput
Provide a renewable and expandable biobank of tumor material from a single PDX, facilitating larger-scale experiments such as high-throughput drug screens that are less feasible with in vivo PDX models.
Cost & Time Efficiency
Enable faster data generation cycles for drug response and functional analyses compared to in vivo PDX studies, optimizing research timelines and resource allocation.
Despite their significant promise, ongoing challenges in PDXO development include the continuous optimization of culture conditions for diverse cancer subtypes, the long-term maintenance of complex tumor microenvironment components, and ensuring consistent stromal cell representation. Our service is specifically designed to monitor and mitigate these challenges through standardized, quality-controlled protocols and rigorous genomic/phenotypic validation at each passage.
| Application Area | Description |
| High-Throughput Drug Screening and Validation | PDXOs enable multiplexed in vitro screens of compound libraries, dose-response matrix testing for combination therapies, and mechanistic research of drug action in a relevant context, prioritizing the most promising candidates for subsequent in vivo trials. |
| Customized Therapy | Predict individual response to inform therapy selection and parallel animal studies. |
| Tumor Biology and Metastasis Research | Investigate mechanisms of tumor initiation, progression, drug resistance, and metastatic spread in a relevant human genomic context. |
| Biomarker Discovery and Validation | Correlating multi-omic profiles (genomic, transcriptomic, proteomic) of PDXOs with their functional drug response data creates a powerful dataset for identifying predictive biomarkers of sensitivity or resistance. |
| Combination Therapy Optimization | The scalability of PDXOs allows for systematic testing of dual and triple drug combinations across a range of concentrations. This facilitates the identification of synergistic or additive interactions and optimization of dosing schedules. |
| Microenvironment and Immuno-Oncology Studies | PDXOs can be co-cultured with autologous or allogeneic immune cells (e.g., T cells, NK cells), cancer-associated fibroblasts (CAFs), or endothelial cells to reconstruct critical tumor-immune and stromal interactions. |
Leveraging the translational value of the PDXO platform and our deep expertise in 3D tumor model development, we offer end-to-end, customized PDX-derived organoid development services. From PDX model generation and initial organoid establishment to full characterization, expansion, and functional assay execution, our team ensures the generation of robust, physiologically relevant models that seamlessly integrate into your oncology research pipeline.
Alfa Cytology's service portfolio encompasses the development of PDX-derived Organoids from a wide spectrum of solid tumor malignancies. We possess established protocols and specialized media formulations tailored to the unique biological requirements of different cancer types, ensuring high success rates in organoid establishment and culture.
Understanding that each research project has unique demands, our service is built around flexible, customized solutions. We collaborate closely with clients to tailor every aspect of the PDXO development process to their specific scientific questions and resource requirements.
Develop advanced 3D co-culture systems by introducing patient-derived or engineered stromal components, such as CAFs, immune cells, or endothelial cells, to study paracrine signaling and therapy response in a more physiologic context.
Precision Genetic Engineering
Utilizing lentiviral transduction or gene editing, we engineer PDXOs to incorporate fluorescent/luminescent reporters for live-cell imaging, create gene knock-out/knock-in models to study gene function, or introduce specific mutations to model resistance.
Dedicated Characterization Suites
Beyond standard QC, we design project-specific validation packages. This may include spatial transcriptomics, live-cell imaging for dynamic response, secretory cytokine profiling, or in-depth analysis of specific signaling pathways (e.g., phospho-protein arrays).
Integration with Advanced Culture Platforms
We can adapt PDXO cultures to specialized platforms such as microfluidic "organ-on-a-chip" devices for studying perfusion and metastasis, or bioprinted structures for precise spatial organization and high-content screening formats.
Beyond model development, we offer a full suite of downstream research services utilizing your established PDXO lines, providing an end-to-end solution for your preclinical studies.
Organoid Model-based Basic Research Services
Utilizing PDXOs for fundamental cancer biology investigations, including proliferation assays, apoptosis detection, cell cycle analysis, invasion/migration studies, and detailed molecular profiling. These services provide deep mechanistic insights into tumor behavior and pathway activity.
Organoid Model-based Preclinical Research Services
Focused on translating basic findings towards therapeutic applications, these services include in vitro drug sensitivity testing (monotherapy and combination), dose-response analysis, pharmacodynamic biomarker assessment, and therapy resistance research. Data from these assays are critical for informing in vivo study design and candidate drug selection.
Alfa Cytology developed a PDX-derived organoid model for ovarian cancer research. In this case study, PDXOs were successfully established from solid tumors of ovarian cancer PDX models. The organoids formed within a specialized 3D matrix culture system. To validate the model's predictive capability, the PDXOs were subjected to a drug sensitivity assay, testing standard first-line chemotherapy agents including drug A, drug B, and their combination. Cell viability was measured after therapy using a luminescent ATP quantification assay. The results demonstrated that PDXOs derived from platinum-sensitive patients showed a significant reduction in viability upon therapy, with the combination therapy being most effective. Critically, the drug response profile of the PDXOs closely mirrored the known response of the source patients. These results confirmed that our PDXO platform reliably preserves the original tumor's key pharmacological characteristics, establishing it as a robust preclinical tool for evaluating patient-specific therapeutic responses and personalized therapy strategies.
Fig.1 PDX-derived organoids established from platinum-sensitive patients were treated with drug A, drug B, or the combination. Viability was quantified and is expressed as a percentage relative to untreated controls. Data are presented as mean ± SEM (n=5; ***p < 0.001).
By providing reliable, relevant PDX-derived organoid models and a full spectrum of associated research services, Alfa Cytology empowers our clients to advance their oncology programs with greater confidence and efficiency. For detailed project discussions, quotations, or to access our scientific support, please contact our team to explore how our PDXO services can be tailored to meet your specific research needs.
Reference
For research use only.
Alfa Cytology is a preclinical research service provider specializing in tumor organoid development. We provide one-stop services that include tailored 3D cancer models, organoid-based research services, and related products to accelerate the discovery and development of cancer therapeutics.
Copyright © 2026 Alfa Cytology. All rights reserved.